Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01664676|
Recruitment Status : Completed
First Posted : August 14, 2012
Last Update Posted : February 28, 2014
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Mellitus||Drug: Liraglutide Drug: Placebo-liraglutide||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients|
|Study Start Date :||December 2012|
|Primary Completion Date :||February 2014|
|Study Completion Date :||February 2014|
1.2 mg liraglutide sc. (single-dose)
Other Name: Victoza
Placebo Comparator: Placebo-liraglutide
Placebo liraglutide sc. (single-dose)
Other Name: Isotonic saline
- Glomerular Filtration Rate (51Cr-EDTA plasma clearance) [ Time Frame: 10-15 hours post-dose ]
- Renal Blood Flow (functional magnetic resonance imaging) [ Time Frame: 15 hours post-dose ]
- Renal electrolyte clearance [ Time Frame: 10-15 hours post-dose ]Sodium, potassium, calcium, lithium and osmotically active substances.
- Excretion of kidney injury markers [ Time Frame: 0-10 hours and 10-15 hours post-dose ]Albumin, NGAL, KIM-1, angiotensinogen and 8-OHdG.
- Plasma concentrations of various hormones [ Time Frame: 10-15 hours post-dose ]Angiotensin II, renin, aldosterone, atrial natriuretic peptide, catecholamines.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01664676
|Aarhus University Hospital, Department of Endocrinology and Diabetes|
|Aarhus, Denmark, 8000|
|Principal Investigator:||Jens S Christiansen, Professor||Aarhus University Hospital, Department of Endocrinology and Diabetes|